Mark Juravic - Academia.edu (original) (raw)

Papers by Mark Juravic

L'invention porte sur un dispositif de dilatation vaginale qui peut comprendre un nombre quel... more L'invention porte sur un dispositif de dilatation vaginale qui peut comprendre un nombre quelconque de caracteristiques. Une caracteristique du dispositif de dilatation vaginale est qu'il est concu pour dilater le tissu vaginal pendant le travail afin d'empecher une lesion de tissu. Une autre caracteristique du dispositif de dilatation vaginale est qu'il peut etre commande manuellement pour dilater le tissu vaginal, ou etre commande automatiquement pour dilater le tissu vaginal. Dans certains modes de realisation, le dispositif de dilatation vaginale est concu pour mesurer une force appliquee par le dispositif sur le tissu. Dans d'autres modes de realisation, le dispositif de dilatation vaginale est concu pour appliquer une force constante sur le tissu. Dans d'autres modes de realisation, le dispositif de dilatation vaginale est concu pour se deployer a une vitesse constante. L'invention porte egalement sur des procedes associes a l'utilisation du dis...

L'invention concerne un boitier de forme elliptique, qui contient une source de lumiere ultra... more L'invention concerne un boitier de forme elliptique, qui contient une source de lumiere ultraviolette et une source d'energie. Un raccord est monte de facon amovible dans le boitier et est desinfecte ou sterilise par lumiere ultraviolette. Un revetement de reflexion a l'interieur du boitier ameliore l'intensite de la lumiere ultraviolette pour desinfecter ou steriliser le raccord. Selon certains modes de realisation, un dispositif destine a etre utilise en dialyse comprend un corps tubulaire allonge ayant une premiere extremite, une seconde extremite et une lumiere s'etendant entre la premiere extremite et la seconde extremite, et une premiere source de rayons ultraviolets associee au corps tubulaire allonge, la premiere source de rayons ultraviolets etant configuree pour diriger la lumiere ultraviolette de facon a steriliser au moins une partie du corps tubulaire allonge.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010

: The purpose of this study was to evaluate the implantability of a novel epicardial mitral annul... more : The purpose of this study was to evaluate the implantability of a novel epicardial mitral annuloplasty device and its ability to reduce the septal-lateral (S-L) dimension of the mitral annulus. : The devices were implanted on the beating heart in 2 healthy dogs (the 24-mm long device in dog A and the 27-mm and 24-mm standard devices in dog B) by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The devices were secured with titanium helical tacks driven through the device into the ventricular wall. Two-dimensional epicardial echocardiograms were performed before and after device implantation to evaluate the degree of mitral regurgitation (MR) and the S-L dimension. : Device implantation was uneventful, taking only ∼30 seconds to deploy. MR (1+) in both dogs at baseline was reduced to zero after implant. The reductions in S-L dimension in systole for the 24-mm device were 7.5% in dog A and 30.5% in dog B. For the 27-mm device in dog B, S-L reduction in systole was 29.9%. The leaflet coaptation length was increased in both cases. : The new device was effective in reducing S-L dimension and 1+ MR without requiring the use of cardiopulmonary bypass. We are currently evaluating this device for the treatment of MR in a rapid-pacing canine heart failure model.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010

: The purpose of this study was to evaluate the implantability of a novel epicardial mitral annul... more : The purpose of this study was to evaluate the implantability of a novel epicardial mitral annuloplasty device and its ability to reduce the septal-lateral (S-L) dimension of the mitral annulus. : The devices were implanted on the beating heart in 2 healthy dogs (the 24-mm long device in dog A and the 27-mm and 24-mm standard devices in dog B) by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The devices were secured with titanium helical tacks driven through the device into the ventricular wall. Two-dimensional epicardial echocardiograms were performed before and after device implantation to evaluate the degree of mitral regurgitation (MR) and the S-L dimension. : Device implantation was uneventful, taking only ∼30 seconds to deploy. MR (1+) in both dogs at baseline was reduced to zero after implant. The reductions in S-L dimension in systole for the 24-mm device were 7.5% in dog A and 30.5% in dog B. For the 27-mm device in dog B, S-L reduction in systole was 29.9%. The leaflet coaptation length was increased in both cases. : The new device was effective in reducing S-L dimension and 1+ MR without requiring the use of cardiopulmonary bypass. We are currently evaluating this device for the treatment of MR in a rapid-pacing canine heart failure model.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #

L'invention porte sur un dispositif de dilatation vaginale qui peut comprendre un nombre quel... more L'invention porte sur un dispositif de dilatation vaginale qui peut comprendre un nombre quelconque de caracteristiques. Une caracteristique du dispositif de dilatation vaginale est qu'il est concu pour dilater le tissu vaginal pendant le travail afin d'empecher une lesion de tissu. Une autre caracteristique du dispositif de dilatation vaginale est qu'il peut etre commande manuellement pour dilater le tissu vaginal, ou etre commande automatiquement pour dilater le tissu vaginal. Dans certains modes de realisation, le dispositif de dilatation vaginale est concu pour mesurer une force appliquee par le dispositif sur le tissu. Dans d'autres modes de realisation, le dispositif de dilatation vaginale est concu pour appliquer une force constante sur le tissu. Dans d'autres modes de realisation, le dispositif de dilatation vaginale est concu pour se deployer a une vitesse constante. L'invention porte egalement sur des procedes associes a l'utilisation du dis...

L'invention concerne un boitier de forme elliptique, qui contient une source de lumiere ultra... more L'invention concerne un boitier de forme elliptique, qui contient une source de lumiere ultraviolette et une source d'energie. Un raccord est monte de facon amovible dans le boitier et est desinfecte ou sterilise par lumiere ultraviolette. Un revetement de reflexion a l'interieur du boitier ameliore l'intensite de la lumiere ultraviolette pour desinfecter ou steriliser le raccord. Selon certains modes de realisation, un dispositif destine a etre utilise en dialyse comprend un corps tubulaire allonge ayant une premiere extremite, une seconde extremite et une lumiere s'etendant entre la premiere extremite et la seconde extremite, et une premiere source de rayons ultraviolets associee au corps tubulaire allonge, la premiere source de rayons ultraviolets etant configuree pour diriger la lumiere ultraviolette de facon a steriliser au moins une partie du corps tubulaire allonge.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010

: The purpose of this study was to evaluate the implantability of a novel epicardial mitral annul... more : The purpose of this study was to evaluate the implantability of a novel epicardial mitral annuloplasty device and its ability to reduce the septal-lateral (S-L) dimension of the mitral annulus. : The devices were implanted on the beating heart in 2 healthy dogs (the 24-mm long device in dog A and the 27-mm and 24-mm standard devices in dog B) by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The devices were secured with titanium helical tacks driven through the device into the ventricular wall. Two-dimensional epicardial echocardiograms were performed before and after device implantation to evaluate the degree of mitral regurgitation (MR) and the S-L dimension. : Device implantation was uneventful, taking only ∼30 seconds to deploy. MR (1+) in both dogs at baseline was reduced to zero after implant. The reductions in S-L dimension in systole for the 24-mm device were 7.5% in dog A and 30.5% in dog B. For the 27-mm device in dog B, S-L reduction in systole was 29.9%. The leaflet coaptation length was increased in both cases. : The new device was effective in reducing S-L dimension and 1+ MR without requiring the use of cardiopulmonary bypass. We are currently evaluating this device for the treatment of MR in a rapid-pacing canine heart failure model.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010

: The purpose of this study was to evaluate the implantability of a novel epicardial mitral annul... more : The purpose of this study was to evaluate the implantability of a novel epicardial mitral annuloplasty device and its ability to reduce the septal-lateral (S-L) dimension of the mitral annulus. : The devices were implanted on the beating heart in 2 healthy dogs (the 24-mm long device in dog A and the 27-mm and 24-mm standard devices in dog B) by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The devices were secured with titanium helical tacks driven through the device into the ventricular wall. Two-dimensional epicardial echocardiograms were performed before and after device implantation to evaluate the degree of mitral regurgitation (MR) and the S-L dimension. : Device implantation was uneventful, taking only ∼30 seconds to deploy. MR (1+) in both dogs at baseline was reduced to zero after implant. The reductions in S-L dimension in systole for the 24-mm device were 7.5% in dog A and 30.5% in dog B. For the 27-mm device in dog B, S-L reduction in systole was 29.9%. The leaflet coaptation length was increased in both cases. : The new device was effective in reducing S-L dimension and 1+ MR without requiring the use of cardiopulmonary bypass. We are currently evaluating this device for the treatment of MR in a rapid-pacing canine heart failure model.

European Journal of Cardio-Thoracic Surgery, 2010

Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touc... more Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 AE 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly ( p = 0.003) reduced from 3.1 AE 1.1 at baseline to 1.4 AE 0.8 after device implantation. The S-L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 AE 0.4 cm at baseline to 2.3 AE 0.3 cm after device implantation (% reduction: 15.1 AE 10.6%). The mitral valve coaptation length was significantly ( p = 0.0001) increased from 0.36 AE 0.11 cm to 0.50 AE 0.08 cm, and the mitral valve tethering area was significantly ( p = 0.0003) decreased from 1.36 AE 0.38 cm 2 to 0.81 AE 0.29 cm 2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions. #